CJC-1295 NO DAC 10mg + IPA 10mg

The CJC-1295 NO DAC 10mg + IPA 10mg blend is a high-purity, research-grade peptide formulation intended exclusively for controlled laboratory investigation of the somatotropic axis and growth hormone regulation.

CJC-1295 (NO DAC) is a synthetic Growth Hormone-Releasing Hormone analogue and a shorter-acting version of CJC-1295 that does not include the Drug Affinity Complex (DAC). It allows for more precise temporal assessment of growth hormone release in experimental models.

Ipamorelin is a synthetic growth hormone secretagogue designed to selectively stimulate growth hormone release in research models with minimal interaction with other endocrine pathways.

Research focus areas:

• Hypertrophic Signalling: Examine the regulation of IGF-1 expression and its involvement in tissue repair, muscle protein synthesis, and bone density maintenance.
• Metabolic Efficiency: Effects on basal metabolic rate, fat oxidation, and nitrogen balance in experimental models.
• Selective Potency: Ipamorelin is noted for its receptor selectivity, with research indicating minimal influence on prolactin, cortisol, or ACTH, making it useful for studying isolated growth hormone signalling pathways.
• Recovery and Sleep Architecture: Assess how pulsatile growth hormone release may relate to circadian rhythms and deep sleep recovery processes.